The present study aims to investigate
the perspectives of health care professionals with prescribing
privileges--including physicians, physician assistants, and nurse
practitioners--regarding various aspects of prescription drug
promotion. Specifically, the survey will address DTC advertising,
professional promotion, use of new technologies including social
media, and the Office of Prescription Drug Promotion's (OPDP's) Bad
Ad program. This is the first such study to our knowledge that
examines the beliefs of health care professionals other than
physicians who now have prescribing privileges. The study findings
will inform FDA of relevant issues and concerns relating to health
care professional exposure to prescription drug promotion.
Daniel Gitteson 3017965156
daniel.gitteson@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.